terbinafin medical valley tafla 250 mg
medical valley invest ab - terbinafinum hýdróklóríð - tafla - 250 mg
metrobactin vet tafla 250 mg
dechra regulatory b.v. - metronidazolum inn - tafla - 250 mg
oviderm krem 250 mg/g
galenica ab - propylene glycol - krem - 250 mg/g
salmeterol/fluticasone neutec (salmeterol/fluticasone wellnex) innöndunarduft, afmældir skammtar 50 míkróg/250 míkróg/skammt
neutec inhaler ireland limited - salmeterolum xínafóat; fluticasonum própíónat - innöndunarduft, afmældir skammtar - 50 míkróg/250 míkróg/skammt
norgesic 35 mg/450 mg tafla 35+450 mg
viatris aps - orphenadrinum cítrat; paracetamolum inn - tafla - 35+450 mg
salmex innöndunarduft, afmældir skammtar 50 míkróg/250 míkróg/skammt
glenmark pharmaceuticals nordic ab* - salmeterolum xínafóat; fluticasonum própíónat - innöndunarduft, afmældir skammtar - 50 míkróg/250 míkróg/skammt
seretide innúðalyf, dreifa 25/250 míkróg/skammt
glaxosmithkline pharma a/s - salmeterolum xínafóat; fluticasonum própíónat - innúðalyf, dreifa - 25/250 míkróg/skammt
naproxen viatris (naproxen mylan) tafla 500 mg
viatris limited - naproxenum inn - tafla - 500 mg
recarbrio
merck sharp & dohme b.v. - imipenem einhýdrat, cílastatín járn, relebactam einhýdrat - gramm-neikvæð bakteríusýkingum - carbapenems, antibacterials for systemic use, - recarbrio is indicated for:- treatment of hospital-acquired pneumonia (hap), including ventilator associated pneumonia (vap), in adults (see sections 4. 4 og 5. - treatment of bacteraemia that occurs in association with, or is suspected to be associated with hap or vap, in adults. - treatment of infections due to aerobic gram-negative organisms in adults with limited treatment options (see sections 4. 2, 4. 4 og 5. Íhuga ætti að opinbera leiðsögn á réttri notkun af sýklalyfjum.
nplate
amgen europe b.v. - romiplostim - purpura, blóðflagnafæð, blóðflagnafæð - antihemorrhagics - adults:nplate is indicated for the treatment of primary immune thrombocytopenia (itp) in adult patients who are refractory to other treatments (e. barkstera, immúnóglóbúlín). paediatrics:nplate is indicated for the treatment of chronic primary immune thrombocytopenia (itp) in paediatric patients one year of age and older who are refractory to other treatments (e. barkstera, immúnóglóbúlín).